登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C16H14F3N5O
化学文摘社编号:
分子量:
349.31
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
产品名称
伏立康唑, European Pharmacopoeia (EP) Reference Standard
InChI
1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1
SMILES string
C[C@@H](c1ncncc1F)[C@](O)(Cn2cncn2)c3ccc(F)cc3F
InChI key
BCEHBSKCWLPMDN-MGPLVRAMSA-N
grade
pharmaceutical primary standard
API family
voriconazole
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
伏立康唑是一种抗真菌药，可抑制麦角固醇的合成。
伏立康唑是用于治疗严重真菌感染的抗真菌药。伏立康唑通过抑制 CYP450 依赖性 14-α甾醇脱甲基酶来抑制麦角固醇合成，从而导致真菌细胞膜中的麦角固醇减少。
Application
Voriconazole EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
signalword
Danger
Hazard Classifications
Acute Tox. 3 Oral - Aquatic Chronic 3 - Carc. 2 - Muta. 2 - Repr. 2 - STOT RE 1 - STOT RE 2 Oral - STOT SE 2 Oral
target_organs
Eyes, Liver,Kidney
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Martyna Mroczyńska et al.
Microorganisms, 8(2) (2020-02-26)
Triazoles are the only compounds used as antibiotics in both medicine and agriculture. The presence of triazoles in the environment can contribute to the acquisition of azole resistance among isolates of Aspergillus fumigatus. The objective of this study was to
Kim Vanstraelen et al.
Antimicrobial agents and chemotherapy, 58(11), 6782-6789 (2014-09-04)
Setting the adequate dose for voriconazole is challenging due to its variable pharmacokinetics. We investigated the impact of hypoalbuminemia (<35 g/liter) on voriconazole pharmacokinetics in adult intensive care unit (ICU) patients treated with voriconazole (20 samples in 13 patients) as
Atsuko Sunada et al.
Ophthalmology, 121(10), 2059-2065 (2014-06-02)
To evaluate the effectiveness of topical agents for the treatment of Acanthamoeba keratitis (AK). Laboratory research. Fifty-six Acanthamoeba isolates from 56 patients with clinically proven AK were studied. The effectiveness of 7 agents against Acanthamoeba cysts was determined in vitro.
Chang Hyun Park et al.
Cornea, 33(9), 928-934 (2014-07-12)
The aim of this study was to evaluate the toxicity of intrastromally injected voriconazole on corneal endothelial cells in rabbits. In total, 32 eyes of 16 rabbits (8 eyes for each group) were divided into 4 groups according to the
Yongxuan Hu et al.
Mycopathologia, 179(1-2), 103-109 (2014-11-05)
Chromoblastomycosis, a chronic fungal infection of skin and subcutaneous tissue caused by dematiaceous fungi, is associated with low cure and high relapse rates. Among all factors affecting clinical outcome, etiological agents have an important position. In southern China, Fonsecaea pedrosoi
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持